IL285680A - Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) - Google Patents
Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)Info
- Publication number
- IL285680A IL285680A IL285680A IL28568021A IL285680A IL 285680 A IL285680 A IL 285680A IL 285680 A IL285680 A IL 285680A IL 28568021 A IL28568021 A IL 28568021A IL 285680 A IL285680 A IL 285680A
- Authority
- IL
- Israel
- Prior art keywords
- crispr
- rho
- rna
- compositions
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810320P | 2019-02-25 | 2019-02-25 | |
| PCT/US2020/019766 WO2020176552A1 (en) | 2019-02-25 | 2020-02-25 | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL285680A true IL285680A (en) | 2021-10-31 |
Family
ID=69960739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285680A IL285680A (en) | 2019-02-25 | 2021-08-17 | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220133768A1 (enExample) |
| EP (1) | EP3931326A1 (enExample) |
| JP (1) | JP2022521764A (enExample) |
| KR (1) | KR20210133993A (enExample) |
| CN (1) | CN113631710A (enExample) |
| AU (1) | AU2020227740A1 (enExample) |
| CA (1) | CA3130515A1 (enExample) |
| IL (1) | IL285680A (enExample) |
| WO (1) | WO2020176552A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3119301A1 (en) * | 2018-11-08 | 2020-05-14 | National University Corporation Tokai National Higher Education And Research System | Gene therapy employing genome editing with single aav vector |
| WO2021122944A1 (en) * | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
| WO2022094363A1 (en) * | 2020-11-01 | 2022-05-05 | University of South Alabama Foundation for Research and Commercialization | Barcoded cells engineered with heterozygous genetic diversity |
| WO2022221741A1 (en) * | 2021-04-16 | 2022-10-20 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| WO2023285431A1 (en) * | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
| AU2023326046A1 (en) * | 2022-08-16 | 2025-02-20 | Adelaide university | Agent for treating or preventing a dominantly-inherited disease |
| CA3267752A1 (en) * | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
| EP4590819A2 (en) * | 2022-09-20 | 2025-07-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions to control gene using genome editing |
| CN116555259B (zh) * | 2023-04-20 | 2024-02-27 | 云舟生物科技(广州)股份有限公司 | 核酸分子及其作为启动子的应用 |
| WO2025090637A2 (en) * | 2023-10-23 | 2025-05-01 | Prime Medicine, Inc. | Genome editing compositions and methods for treatment of retinitis pigmentosa |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| JP7103750B2 (ja) * | 2013-12-12 | 2022-07-20 | ザ・ブロード・インスティテュート・インコーポレイテッド | ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用 |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| WO2015188056A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| ES2788426T3 (es) * | 2014-06-16 | 2020-10-21 | Univ Johns Hopkins | Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1 |
| US20160324987A1 (en) * | 2015-04-15 | 2016-11-10 | Cedars-Sinai Medical Center | Use of crispr/cas9 as in vivo gene therapy to generate targeted genomic disruptions in genes bearing dominant mutations for retinitis pigmentosa |
| EP3289080B1 (en) * | 2015-04-30 | 2021-08-25 | The Trustees of Columbia University in the City of New York | Gene therapy for autosomal dominant diseases |
| US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
| KR20190039703A (ko) * | 2016-07-05 | 2019-04-15 | 더 존스 홉킨스 유니버시티 | Crispr/cas9-기반 조성물 및 망막 변성을 치료하기 위한 방법 |
| CN110168084A (zh) | 2016-12-05 | 2019-08-23 | 爱迪塔斯医药公司 | 用于内源和来源DNA的单发指导RNA(ogRNA)靶向的系统和方法 |
| EP3622070A2 (en) * | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| CA3082450A1 (en) * | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| CN112153990A (zh) * | 2018-03-23 | 2020-12-29 | 纽约市哥伦比亚大学理事会 | 用于常染色体显性疾病的基因编辑 |
-
2020
- 2020-02-25 CA CA3130515A patent/CA3130515A1/en active Pending
- 2020-02-25 AU AU2020227740A patent/AU2020227740A1/en not_active Abandoned
- 2020-02-25 WO PCT/US2020/019766 patent/WO2020176552A1/en not_active Ceased
- 2020-02-25 EP EP20714062.5A patent/EP3931326A1/en active Pending
- 2020-02-25 CN CN202080025160.5A patent/CN113631710A/zh active Pending
- 2020-02-25 US US17/433,975 patent/US20220133768A1/en active Pending
- 2020-02-25 KR KR1020217030652A patent/KR20210133993A/ko active Pending
- 2020-02-25 JP JP2021549698A patent/JP2022521764A/ja active Pending
-
2021
- 2021-08-17 IL IL285680A patent/IL285680A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020176552A1 (en) | 2020-09-03 |
| JP2022521764A (ja) | 2022-04-12 |
| CN113631710A (zh) | 2021-11-09 |
| AU2020227740A1 (en) | 2021-10-07 |
| CA3130515A1 (en) | 2020-09-03 |
| US20220133768A1 (en) | 2022-05-05 |
| KR20210133993A (ko) | 2021-11-08 |
| EP3931326A1 (en) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285680A (en) | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) | |
| IL285782A (en) | Compounds, compositions, and methods for treating disease | |
| IL288278A (en) | Alternative 1-oxo-isoindolin-5-carboxamide compounds, compounds thereof, and methods of treatment therewith | |
| EP3619308A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| WO2017106364A3 (en) | Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13 | |
| SG11202107325TA (en) | Methods and compositions for the treatment of fabry disease | |
| EP3720421A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISEASES | |
| EP3818081A4 (en) | COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME-RELATED DISEASES OR DISORDERS | |
| EP3852877A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINITIS PIGMENTOSA | |
| IL279091A (en) | Preparations and methods for the treatment of dominant pigmentary retinitis | |
| EP3846843A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASES | |
| EP3870210A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF FIBROSIS | |
| MX2019004375A (es) | Inhibidores de bromodominios. | |
| IL277635A (en) | Preparations and methods for the treatment of catecholaminergic polymorphic ventricular tachycardia transmitted by dominant inheritance | |
| EP3579825A4 (en) | SULPHAMOYLTHIOPHENAMIDE DERIVATIVES AND USES THEREOF AS MEDICINES FOR TREATMENT OF LIVER FIBROSIS | |
| IL265242B (en) | Compounds for the treatment of hypertension and/or fibrosis | |
| EP3481376A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND / OR PREVENTION OF LYSOSOMAL STORAGE DISEASES AND OTHER MONOGENIC METABOLIC DISEASES | |
| HK1262960A1 (en) | Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13 | |
| HK40115056A (en) | Compositions and methods for the treatment of proteopathies | |
| HK40045608A (en) | Compositions and methods for treatment of dominant retinitis pigmentosa | |
| AU2019903606A0 (en) | Method and Compositions for the Treatment of Disease | |
| HK40082144A (en) | Use of masitinib for the treatment of eosinophilic asthma | |
| HK40067211A (en) | Composition for the treatment of muscle wasting | |
| AU2019901644A0 (en) | Compositions for the Treatment of Diseases and Conditions |